Cargando…
Assessing the Safety of a Cell-Based Immunotherapy for Brain Cancers Using a Humanized Model of Hematopoiesis
Despite a surge in the preclinical development of immunotherapies, current models are unable to predict putative toxicity, particularly the “on-target, off-tumor” effects of these therapeutics. To address this gap, we used a humanized mouse model of hematopoiesis to examine the toxicity profile of C...
Autores principales: | Salim, Sabra K., Xu, Joshua, Wong, Nicholas, Venugopal, Chitra, Hope, Kristin J., Singh, Sheila K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756979/ https://www.ncbi.nlm.nih.gov/pubmed/33377018 http://dx.doi.org/10.1016/j.xpro.2020.100124 |
Ejemplares similares
-
In vitro evaluation of CAR-T cells in patient-derived glioblastoma models
por: Brakel, Benjamin A., et al.
Publicado: (2021) -
Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma
por: Tatari, Nazanin, et al.
Publicado: (2020) -
Derivation and culturing of neural stem cells from human embryonic brain tissue
por: Suk, Yujin, et al.
Publicado: (2022) -
Advances in Immunotherapy for Adult Glioblastoma
por: Chokshi, Chirayu R., et al.
Publicado: (2021) -
A Patient-Derived Xenograft Model of Glioblastoma
por: Chokshi, Chirayu R., et al.
Publicado: (2020)